Nymox Pharmaceutical has filed to seek approval for marketing authorization for Fexapotide Triflutate to treat symptoms of benign prostatic hyperplasia in five European countries.

Nymox Pharmaceutical (NASDAQ:NYMX) has filed to seek approval for marketing authorization for Fexapotide triflutate to treat symptoms of benign prostatic hyperplasia in five European countries.
As quoted in the press release:

“Fexapotide has the real potential to alter the way BPH will be treated in the future. There is a major unmet medical need for a safe and efficacious treatment method for the many men who suffer from this age-related malady,” said Dr. Paul Averback, CEO of Nymox.
“This first filing represents a major corporate milestone for the development of Fexapotide. We are extremely pleased to achieve this milestone which is based on intensive work carried out by our teams and many expert collaborators over the past 15 years,” Dr. Averback added.
Erik Danielsen, Nymox’s CFO added, “Going forward, we expect to announce further regulatory filings for approval in additional important jurisdictions around the world as well as corporate initiatives supporting our pre-commercialization efforts. We now plan to significantly step up our communication programs with both the medical as well as the financial communities. Today’s important step forward will be followed up by additional strategic business development activities.”

Click here to read the full press release.

Source: globenewswire.com

business development europe fexapotide triflutate marketing approval marketing authorization\nymox nymox pharmaceutical Pharmaceutical Investing